首页> 外文期刊>Oncology reports >Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer
【24h】

Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer

机译:miR-136的表达与人类上皮性卵巢癌的原发顺铂耐药性相关

获取原文
获取原文并翻译 | 示例
           

摘要

MicroRNAs (miRNAs) are involved in regulating the response of cancer cells to various therapeutic interventions, yet their involvement in the chemoresistance of human epithelial ovarian cancer is not fully understood. We found that miR-136 was significantly downregulated in specimens from patients with chemoresistant epithelial ovarian cancer. In the present study, we aimed to clarify the role of miR-136 in regulating the chemoresistance of ovarian cancer. Thirty-four tumor bank specimens and 2 well-established human ovarian cancer cell lines, C13 and 0V2008, were used. We found that miR-136 expression was significantly reduced in primary platinum-resistant patients and the ovarian cancer OVC cell line. Enforced expression of miR-136 decreased the chemoresistance to cisplatin in OVC cells through inhibition of cell survival. In addition, we found no association between miR-136 and migration or invasion potential in the ovarian cancer cell lines. However, in the platinum-resistant C13 cell line, the overexpression of miR-136 markedly promoted an apoptotic response to cisplatin. Furthermore, the levels of adducts corrected with their extent of DNA damage/repair, in terms of the percentage of DNA in comet tails, tail length, tail moment (TM), and olive tail moment (OTM), revealed that miR-136 is essential for the repair of cisplatin-induced DNA damage. Our findings suggest that miR-136 may function as an anti-oncogene and deficiency of miR-136 expression in ovarian cancer can induce chemoresistance at least in part by downregulating apoptosis and promoting the repair of cisplatin-induced DNA damage. Thus, miR-136 may provide a biomarker for predicting the chemosensitivity to cisplatin in patients with epithelial ovarian cancer.
机译:MicroRNA(miRNA)参与调节癌细胞对各种治疗性干预的反应,但尚未完全了解它们与人上皮性卵巢癌的化学抗性有关。我们发现,miR-136在具有化学耐药性上皮性卵巢癌患者的标本中显着下调。在本研究中,我们旨在阐明miR-136在调节卵巢癌化学耐药性中的作用。使用了34个肿瘤库标本和2个成熟的人类卵巢癌细胞系C13和0V2008。我们发现在原发性铂耐药患者和卵巢癌OVC细胞系中,miR-136表达显着降低。通过抑制细胞存活,miR-136的强制表达降低了OVC细胞对顺铂的化学耐药性。此外,我们发现miR-136与卵巢癌细胞系中的迁移或侵袭潜能没有关联。但是,在抗铂的C13细胞系中,miR-136的过度表达明显促进了对顺铂的凋亡反应。此外,根据彗星尾巴中DNA的百分比,尾巴长度,尾部矩(TM)和橄榄尾部矩(OTM)对DNA损伤/修复程度进行校正的加合物水平表明,miR-136是对于修复顺铂引起的DNA损伤至关重要。我们的发现表明,miR-136可能起着抗癌基因的作用,而miR-136在卵巢癌中的表达不足可以至少部分地通过下调细胞凋亡并促进顺铂诱导的DNA损伤的修复来诱导化学耐药性。因此,miR-136可能为预测上皮性卵巢癌患者对顺铂的化学敏感性提供生物标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号